| Literature DB >> 19520806 |
Stefan Costinean1, Sukhinder K Sandhu, Irene M Pedersen, Esmerina Tili, Rossana Trotta, Danilo Perrotti, David Ciarlariello, Paolo Neviani, Jason Harb, Lauren Rachel Kauffman, Aaditya Shidham, Carlo Maria Croce.
Abstract
We showed that Emicro-MiR-155 transgenic mice develop acute lymphoblastic leukemia/high-grade lymphoma. Most of these leukemias start at approximately 9 months irrespective of the mouse strain. They are preceded by a polyclonal pre-B-cell proliferation, have variable clinical presentation, are transplantable, and develop oligo/monoclonal expansion. In this study, we show that in these transgenic mice the B-cell precursors have the highest MiR-155 transgene expression and are at the origin of the leukemias. We determine that Src homology 2 domain-containing inositol-5-phosphatase (SHIP) and CCAAT enhancer-binding protein beta (C/EBPbeta), 2 important regulators of the interleukin-6 signaling pathway, are direct targets of MiR-155 and become gradually more down-regulated in the leukemic than in the preleukemic mice. We hypothesize that miR-155, by down-modulating Ship and C/EBPbeta, initiates a chain of events that leads to the accumulation of large pre-B cells and acute lymphoblastic leukemia/high-grade lymphoma.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19520806 PMCID: PMC2727407 DOI: 10.1182/blood-2009-05-220814
Source DB: PubMed Journal: Blood ISSN: 0006-4971 Impact factor: 22.113